TCR2Therapeutics Inc. announced an expansion of its leadership team to strengthen expertise in manufacturing, Investigational New Drug (IND) enablement and innovation as the Company advances its approach of creating next generation TRuCTM-T cells addressing the tumor microenvironment. Nigel Williams joins TCR2 as Vice President of Manufacturing. Most recently, he served at OvaScience as Senior Vice President of Global Technical Development and Operations, where he held numerous responsibilities including clinical and commercial operations management, building and qualifying multiple global GMP cell processing laboratories, developing a global supply chain and executing improvement processes and practices across the organization. Robert Tighe joins TCR2 as Vice President of Translational Research. Previously, he served as Vice President of Translational Immunology and Immunopharmacology at Compass Therapeutics, where he led the discovery and IND approval of CTX-471, a CD137 agonist antibody, and built the cellular immunology and autoimmunity research teams. Dario Gutierrez, Ph.D., joins TCR2 as Vice President of Discovery and Innovation. Previously, he was Director and Head of Investigational Biology and Immuno-Biology in the Merck Exploratory Science Center at Merck & Co., where he was responsible for establishing discovery programs consisting of different modalities such as small molecules, biologics and cell therapy, and a diverse portfolio that includes reverse-translational systems immunology discovery and multiple immuno-oncology target identification efforts. Prior to joining Merck, Dario worked at Evelo Biosciences as a Senior Scientist and Head of Immune Tolerance. Before joining the biotechnology industry, Dario worked as a postdoctoral scientist in the Division of Cellular Immunology at the German Cancer Research Center.